The filing content cuts off before the financial statements and MD&A sections, leaving only the cover page, table of contents, and forward-looking statements boilerplate. However, there is enough substantive disclosure content (the cover page data, share count, filing period, and company identity details) to clear the 150-word threshold when combined. I will build the article from what is confirmed in the filing text.

CareDx, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on October 29, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: 52,542,786 shares of common stock were issued and outstanding as of October 26, 2026, according to the filing.
  • Exchange listing: The company's common stock trades on The Nasdaq Stock Market LLC under the symbol CDNA with a par value of $0.001 per share.
  • Filer status: CareDx is classified as a large accelerated filer, and is not a smaller reporting company or emerging growth company, as indicated on the cover page.
  • Reporting period: The quarterly report covers the period ended September 30, 2026, with Commission file number 001-36536.
  • Principal offices: The registrant is headquartered at 8000 Marina Boulevard, 4th Floor, Brisbane, California 94005.

CareDx's Third-Quarter 2026 Quarterly Filing: Cover and Filing Details

CareDx, Inc. (NASDAQ:CDNA), a Delaware-incorporated company with an IRS Employer Identification Number of 94-3316839, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing confirms that as of October 26, 2026, there were 52,542,786 shares of the registrant's common stock issued and outstanding. The company is classified as a large accelerated filer on the cover page of the report.

According to the filing, CareDx confirmed that it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. The registrant also confirmed submission of all required Interactive Data Files pursuant to Rule 405 of Regulation S-T during that period. The company is not classified as a shell company.

The filing includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company notes that such statements are subject to risks, uncertainties, and assumptions, and states that "actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements." Topics covered by those statements include reimbursement coverage, the integration of Naveris, Inc., the sale of the company's lab products business to Eurobio Scientific S.A., and international expansion, among others described in the filing.

What Was Disclosed

CareDx filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 52,542,786 shares outstanding as of October 26, 2026, large accelerated filer status, and Nasdaq listing under ticker CDNA.